

1. Junior Resident 2. Associate Professor

Kasturba Medical College Manipal, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India

DR.LIKHITH - CV



Professional summary:

- Junior Resident – MD Pharmacology, Kasturba Medical College, Manipal

> Work experiences:

- General Physician (2020-2021) Primary Health Centre, Bengaluru
- Resident doctor (2020)
- Consultant physician (2022-2023, care-on-call)
- Sexologist (2023, Allo health)

> Education:

MD Physician – Kharkiv National Medical University, Ukraine, class of 2019

- > Ongoing research studies: 4
- Certifications & Awards: 8







PRESENTATION OVERVIEW



- What is Off-label drug use ?
- Study Objectives
- Methods and Study procedures
- Results
- Discussion
- Conclusions







INTRODUCTION TO OFF-LABEL DRUG USE

• What is Off-Label Drug Use?

Prescribing drugs for conditions, doses, age groups, or routes not officially approved.

 Rationale: Address the need for insights into off-label drug use practices and associated ethical concerns in India



BACKGROUND: OFF-LABEL DRUG USE

- Why It's Done: Lack of alternatives, clinical experience, or emerging evidence.
- Concerns:
 - Safety risks (ADRs).
 - Efficacy uncertainty.
 - Limited patient consent.
- Challenges:
 - No clear guidelines or incentives for trials





EXAMPLES OF COMMON OFF-LABEL USES OF DRUGS

Category	Drug	Off-Label Use(s)
Allergy	Diphenhydramine	Chemotherapy- related emesis, insomnia
Anesthesiology	Propofol	Intracranial hypertension
	Dexamethasone	Postoperative nausea
Cardiology	Amiodarone	Supraventricular tachycardia



Donnenberg VS et al. J Clin Pharmacol. 2022;62(6):703-705



AIMS & OBJECTIVES

- Primary: To describe the patterns and practices of off-label drug use
- Secondary: To understand the perceived safety and ethical concerns





KASTURBA HOSPITAL MANIPAL

Kasturba Medical College and Kasturba Hospital Institutional Ethics Committee

METHODS - OVERVIEW

T 1/1 ·			Communication of the decision of the Institutional Ethics Committee	
Ethics	IEC Reference Number: 371/2024	Mr. Rajaram Rao (Chairperson	Wednesday 14 th Augu Project title	Practices and Ethical Dilemmas on Off-Label
		Layperson) Dr. Deepak Mallya (Cimicasi)) Dr. Girish Thunga (Scientific Member)	Principal	Medicine use in India - A digital Survey. Dr. Jeffrey Pradeep Raj
	CTRI Reference Number:	Dr. Badareesh L. (Clinician) Dr. Archana G (Scientific Member) Dr. Raesh Kariath (Scientific Member)	Investigator Co Investigators	Dr. Likhith P
	CTRI/2024/10/075563	Dr. Vijetha Shenoy Belle (haw Medical Scientsti Dr. Sanjat G Karrath (haw Medical Scientisti Dr. Viru Thomas George (Scientific Menber) Dr. Mugli T S. (scientific Member)	Name & Address of Institution	Division of Clinical Pharmacology, Department of Pharmacology, Kasturba Medical College Manipal, Department of Pharmacology, Kasturba Medical College, Manipal.
	Written informed consent was obtained	Dr. Murali T.S. (Scentific Member) Ms. Anupama (Legal Espert) Dr. Binil (Scentific Member)	Status of review	: New
	Willien miormed consent was obtained	Dr. Arul Amuthan L(Base Medical Scientist) Dr. Sreenivasa Acharya (Social Scientist) Dr. Muralidhar M Kulkarni	Date of review Decision of the IEC	: 13.08.2024 Approved with modifications till 31.10.2025.
	digitally	(Member Secretary) Standing Instructions	IEC Approval Date	: 16 OCT 2024
	ICMR ethics guidelines 2017	Participants by ICMR, and the SOP of IEC including turby submission of Interrin Annual Report and Final Closure Report • Participant Information Steers and a copy of signed Informed Content shall be given to every research participant (for all	Dr. Muralidhar M Kulkarni MEMBER SECRETARY - KMC & KH IEC	
Study Design	Cross sectional survey	to every research punicipant (for all prospective studies) = Inform IEC in case of any proposed amendments (change in protocol procedure, site Investigator (etc.) = Inform IEC mmediatry in case of any Adverse Events and Serious Adverse Events = Members of IEC have the right to monitor are proper with protocultantiant,		
Sample		If CTU/ HeBC/ CDSCD registration: Ensure registration and cleanace from the respective authorities before the evolution of the first participant. The IEC to be notified about the same within T days of successful registration cleanace. SOP The chargemon endorses the comment		
SIZE	withdrawal).	IEC Secretariat, F Kasturba Medical College, Manipal - 576104	Room No. 22, Ground Floor, Facul 4, Karnataka, India. Phone : +91 -	ty Room Complex. Kasturba Medical College Premises, 0820 - 2933522, Fax : +91 - 0820 - 2571927. Email : lec kmc@manipi



STUDY SETTING

The survey link has been live from 21 October 2024

Interim analysis with data until 04 Nov 2024

Survey Format: Self-administered

Shared on platforms like whatsApp, LinkedIn, Facebook, Twitter and Email, after Institutional Ethics Committee approval





>Inclusions:

Indian > Doctors >18Years

- > Exclusion:
- Incomplete > survey forms







STATISTICAL ANALYSIS PLAN

Data Summary:


- Descriptive Statistics: Mean, standard deviation for continuous data; median and interquartile range if non-normal
- Categorical Data: Frequency and percentages
- Normality Test: Shapiro-Wilk
- Inferential Statistics: Appropriate tests based on variable type and distribution
- Software: SPSS Version 20 or above, with significance level at p < 0.05








Biological sex








Highest educational qualification














N=100




Role Distribution

Levels

Intern Junior faculty/consultant board speciality Junior faculty/consultant super speciality Resident/ PG trainee Senior faculty/consultant board speciality Senior faculty/consultant super speciality







Awareness of off-label drug use





50% 50 =100 N=100 40 39% 34% Lrequency 50 50 Levels Case reports Non-availablity of alternatives Not applicable Personal experience 23% 10 0


Common reason for off-label drug use

FERCAP 2024 - Kathmandu, Nepal






Experience/seen treatment failure after using off-label drugs








Experience/seen ADRs after using off-label drugs







N=100




Frequency of informing to institute recommendations about off-label drug use

FERCAP 2024 - Kathmandu, Nepal







Frequency of taking permission from patients before prescribing off-label drugs






71% N=100 60 Frequency 6 29% 20 0 Yes No

Should all current drugs be trialled in young population to avoid off-label drug use

FERCAP 2024 - Kathmandu, Nepal








All drugs undergo clinical trails at all ages to avoid off-labelling

FERCAP 2024 - Kathmandu, Nepal

24






Should government give incentives to perform clinical trails to avoid off-label prescribing














Major concerns regarding off-label prescription





DISCUSSION: ETHICAL IMPLICATIONS

• High Use, Low Guidance

• Off-label prescribing common (50%) but lacks clear guidelines.

Ethical and Safety Concerns

 Perceived key issues: Treatment failures (28%) and ADRs (9%) raise safety alarms.

Communication Gaps

• Limited/Rare patient communication (43%) and reporting (28.4%).

Need for Oversight and Evidence

 Strong support for clinical trials and ethical frameworks to guide safe off-label use.





CONCLUSION

- High Awareness, but 50% have used drugs off label
- Top Concerns: Safety and efficacy

Recommendations:

- Enhance education on safe off-label practices.
- Support research to validate off-label uses.
- Improve patient communication and consent policies.

